Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum StockZacks Investment Research • 10/14/25
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 10/14/25
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of ZilebesiranBusiness Wire • 10/01/25
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with VutrisiranBusiness Wire • 09/28/25
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum TranscriptSeeking Alpha • 09/23/25
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicinePRNewsWire • 09/18/25
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?Zacks Investment Research • 09/10/25
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior NotesBusiness Wire • 09/10/25
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?Zacks Investment Research • 09/08/25
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks TranscriptSeeking Alpha • 09/03/25
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are PositivesSeeking Alpha • 09/03/25
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II WinZacks Investment Research • 09/01/25
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CMBusiness Wire • 08/31/25
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled HypertensionBusiness Wire • 08/30/25
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes TrialBusiness Wire • 08/30/25
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025Business Wire • 08/11/25
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth ConferenceBusiness Wire • 08/05/25
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock UpZacks Investment Research • 08/01/25